Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Recurso digital |
| Hizkuntza: | |
| Argitaratua: |
Zenodo
2026
|
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.5281/zenodo.19986110 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Aurkibidea:
- <p class="MsoNormal"><span>The field of pharmaceutical sciences is undergoing a paradigm shift from conventional constant-release dosage forms toward "Time-Specific" and "Site-Specific" delivery, collectively known as Pulsatile Drug Delivery Systems (PDDS). These systems are engineered to release a drug rapidly and completely after a predetermined "lag time," which is essential for treating chronic diseases that exhibit circadian fluctuations. This review provides an in-depth analysis of the physiological rationale behind chronotherapy, focusing on conditions such as nocturnal asthma, rheumatoid arthritis, and cardiovascular surges where symptoms peak at specific hours of the day. We categorize PDDS into three primary technological platforms: time-controlled, stimuli-induced (pH, enzyme, and temperature-responsive), and externally regulated (magnetic and ultrasonic) systems. Furthermore, this article evaluates modern formulation strategies, including the use of rupturable coatings, swellable plugs, and osmotic pumps. Special emphasis is placed on proprietary technologies such as Pulsincap™, CODAS®, and OROS®, alongside emerging trends like 3D-printed personalized dosage forms. By synchronizing drug release with the biological clock, PDDS offer a superior alternative to sustained-release systems, significantly improving therapeutic outcomes, reducing systemic toxicity, and enhancing patient compliance.</span></p>